SCHEMBL2821677

SCHEMBL2821677

COc1cnc(-c2ccccn2)nc1Nc1ccc(-c2ccccc2)cn1

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 10/20 0.59
L3MBTL1 Q9Y468 9/20 0.59
SMN1; SMN2 Q16637 7/20 0.59
LMNA P02545 5/20 0.59
MAPT P10636 3/20 0.59
MITF O75030 1/20 0.59
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
ALDH1A1 P00352 3/20 0.50
PPP1CA P62136 3/20 0.50
HTT P42858 2/20 0.50
KDM4E B2RXH2 1/20 0.50
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2824129 0.90 TRPM8 (0.53) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
Hydrochloric Acid SCHEMBL2824980 0.89 TRPM8 (0.52) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL2821106 0.87 CTSC (0.53) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL2822086 0.87 TRPM8 (0.62) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL2820941 0.87 TRPM8 (0.68) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL2822515 0.86 TRPM8 (0.54) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL2821539 0.85 TRPM8 (0.60) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL4902684 0.85 KDR (0.42) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL2821547 0.85 TRPM8 (0.60) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL2820216 0.85 TRPM8 (0.60) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1742634-B1 POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN INC (US) 2010-10-27 EP claimed
US-7560464-B2 Polycyclic pyrimidines as potassium ion channel modulators ICAGEN, INC. (US) 2009-07-14 US claimed
EP-1742634-B1 POLYCYCLIC PYRIMIDINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN INC (US) 2010-10-27 EP disclosed
US-7560464-B2 Polycyclic pyrimidines as potassium ion channel modulators ICAGEN, INC. (US) 2009-07-14 US disclosed
US-20050267089-A1 Polycyclic pyrimidines as potassium ion channel modulators ICAGEN, INC. (US) 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267089-A1 Polycyclic pyrimidines as potassium ion channel modulators KCNJ2, KCNJ1, KCNJ11 TRPM8 61/4885L3MBTL1 4011/4885SMN1; SMN2 3689/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.